| Literature DB >> 35408688 |
Suwapitch Chalongkulasak1, Teerasak E-Kobon2,3, Pramote Chumnanpuen1,3.
Abstract
Acne vulgaris is a common skin disease mainly caused by the Gram-positive pathogenic bacterium, Propionibacterium acnes. This bacterium stimulates the inflammation process in human sebaceous glands. The giant African snail (Achatina fulica) is an alien species that rapidly reproduces and seriously damages agricultural products in Thailand. There were several research reports on the medical and pharmaceutical benefits of these snail mucus peptides and proteins. This study aimed to in silico predict multifunctional bioactive peptides from A. fulica mucus peptidome using bioinformatic tools for the determination of antimicrobial (iAMPpred), anti-biofilm (dPABBs), cytotoxic (ToxinPred) and cell-membrane-penetrating (CPPpred) peptides. Three candidate peptides with the highest predictive score were selected and re-designed/modified to improve the required activities. Structural and physicochemical properties of six anti-P. acnes (APA) peptide candidates were performed using the PEP-FOLD3 program and the four previous tools. All candidates had a random coiled structure and were named APAP-1 ori, APAP-2 ori, APAP-3 ori, APAP-1 mod, APAP-2 mod, and APAP-3 mod. To validate the APA activity, these peptide candidates were synthesized and tested against six isolates of P. acnes. The modified APA peptides showed high APA activity on three isolates. Therefore, our biomimetic mucus peptides could be useful for preventing acne vulgaris and further examined on other activities important to medical and pharmaceutical applications.Entities:
Keywords: Achatina fulica; Propionibacterium acnes; antibacterial peptides; peptidomes; snail mucus
Mesh:
Substances:
Year: 2022 PMID: 35408688 PMCID: PMC9000865 DOI: 10.3390/molecules27072290
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Growth patterns of P. acnes isolates under the clindamycin concentration of 10 µg/mL after 24, 48, and 72 h.
Predictive probability score or SVM scores for bioactive peptide prediction tools.
| APAP-ID. | Number of | Prediction Scores | |||
|---|---|---|---|---|---|
| iAMP | dPABBs | ToxinPred | MLCPP | ||
| APAP1-original | 7 | 0.73 | 1.23 | −0.91 | 0.73 |
| APAP1-modified | 7 | 0.97 | 2.65 | −0.81 | 0.97 |
| APAP2-original | 8 | 0.61 | 0.11 | −1.17 | 0.61 |
| APAP2-modified | 8 | 0.97 | 2.77 | −1.38 | 0.97 |
| APAP3-original | 5 | 0.78 | 0.06 | −0.73 | 0.78 |
| APAP3-modified | 5 | 0.97 | 1.88 | −0.83 | 0.97 |
Selected and modified antibacterial peptide sequences, structures, and physiochemical properties.
| ID | Sequence | Peptide Structure | Physicochemical Properties | |||||
|---|---|---|---|---|---|---|---|---|
| Hydrophobicity | Hydropathicity | Amphipathicity | Hydrophilicity | Charge | MW | |||
| APAP1-original |
|
| −0.57 | −1.27 | 1.22 | 0.61 | 3 | 893.14 |
| APAP1-modified |
|
| −0.19 | 0.07 | 1.08 | 0.06 | 2.5 | 822.13 |
| APAP2-original |
|
| −0.04 | 0.81 | 0.31 | −0.39 | 1 | 856.14 |
| APAP2-modified |
|
| −0.13 | 0.29 | 0.95 | −0.01 | 2.5 | 893.22 |
| APAP3-original |
|
| 0.37 | 2.36 | 0.29 | −1.22 | 0.5 | 551.76 |
| APAP3-modified |
|
| −0.21 | 0.82 | 1.22 | 0.18 | 2 | 627.9 |
Figure 2Inhibition percentage of P. acnes isolates treated with APAP-original and APAP-modified biomimetic peptides. Each biomimetic APAP candidate (20 µg/mL) was tested against six isolates of P. acnes in biological triplicates. Bars indicated significant difference at p < 0.001 (***), p < 0.005 (**) and p < 0.05 (*). Error bars represented standard error of the mean.
Figure 3Bioinformatic virtual screening workflow for finding antibacterial peptide candidates from Achatina fulica mucus peptidome and the in vitro analysis of P. acnes inhibition assay.
IC50 scores of APAP2-original and APAP2-modified peptides again six P. acnes isolates treated at the concentration of 160, 80, 40, 20, 10 and 5 µg/mL.
|
| JB1 | JB9 | JB3 | JB6 | JB7 | JB13 | Mean ± SD | |
|---|---|---|---|---|---|---|---|---|
| Peptide ID | ||||||||
| APAP2-original | 124.346 | 242.24 | 156.29 | 290.82 | 86.6996 | 143.451 | 105.5228 ± 31.41 | |
| APAP2-modified | 155.301 | 96.1367 | 55.2911 | 31.7074 | 29.7781 | 24.9624 | 27.37025 ± 20.95 | |
Percentage of cell viability of human fibroblast cell line treated with APAP2-original and -modified peptides for 24 h.
| Replicates | 1 | 2 | 3 | 4 | Mean | SD | SE | |
|---|---|---|---|---|---|---|---|---|
| Peptide ID | ||||||||
| APAP2-original | 73.89788 | 77.06946 | 90.70726 | 90.3901 | 83.01618 | 8.794591 | 4.397296 | |
| APAP2-modified | 101.1735 | 92.29305 | 94.196 | 81.50967 | 92.29305 | 8.139709 | 4.069854 | |